Abstract:CAR-T cell therapy has been increasingly conducted for cancer patients
in clinical settings. Progress in this therapeutic approach is hampered
by the lack of a solid manufacturing process, T lymphocytes, and
tumor-specific antigens. T-cell source used in CAR-T cell therapy is
predominantly derived from the patient’s own T lymphocytes, which makes
this approach impracticable to patients with progressive diseases and T
leukemia. Autologous CAR-T cell generation is time-consuming due to lack
of readily available … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.